Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07708441 HRS-1780 Resistant hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07708441, evaluating HRS-1780 in Resistant hypertension: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07708753 SYS-6043 Platinum-Resistant Fallopian Tube Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07708753, evaluating SYS-6043 in Platinum-Resistant Fallopian Tube Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07706777 HRS-2129 Primary gout Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07706777, evaluating HRS-2129 in Primary gout: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07708727 GS-3242 HIV Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07708727, evaluating GS-3242 in HIV Infections: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07707973 Temozolomide Glioblastoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07707973, evaluating Temozolomide in Glioblastoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07709585 Carboplatin Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07709585, evaluating Carboplatin in Lung Non-Small Cell Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
8 min read
USP14 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for USP14, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Tenaya Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Tenaya Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
8 min read
USP10 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for USP10, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Verve Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Verve Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Cassava Sciences Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Cassava Sciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
8 min read
USP9X Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for USP9X, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.